BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement
HOUSTON, TX and SUNSHINE COAST, QUEENSLAND / ACCESS Newswire / October 6, 2025 / BrYet US, Inc. (“BrYet”), a biotechnology innovator developing a drug with the potential to be a…
